MiR-132-3p was downregulated in TGF-<i>β</i>1 stimulated Met-5A cells and miR-132-3p mimics and miR-132-3p inhibitor transfected Met-5A cells. by Yangyang Yin (14323701)

Subjects:

Acquisition of Mutant scFv With a Higher Affinity against Wild-type, Beta and Delta SARS-CoV-2 using a HEK 293T Antibody Surface Display Library. by Ye Yang (297214)

Klf5 expression is down-regulated in the ruptured human and experimental AAA. by Dong Ma (584680)

SARS-CoV-2 inhibits SG formation and decreases expression of G3BP1. by Stacia M. Dolliver (13822801)

Spontaneous oxycodone withdrawal initially flattens NREM power rhythms, decreases low frequency and increases high frequency power. by Michael Gulledge (20577135)

AIM-100 reduces dsRNA silencing in body wall muscle and decreases DA neurodegeneration. by Anthony L. Gaeta (13272609)

The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

“…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”

Western blots and a histogram showing steady-state levels of serum RBP4 in cynomolgus monkey and dog. by Boglarka Racz (1336803)

Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF by Inés Barbeito (5864351)

“…Background<p>We estimated the association between the level of restriction in nine different fields of activity and SARS-CoV-2 transmissibility in Spain, from 15 September 2020 to 9 May 2021.</p>Methods<p>A stringency index (0–1) was created for each Spanish province (n = 50) daily. …”

Association of chemotherapy cycles and nausea and vomiting with the decrease of post-treatment vitamin D concentration (n = 136). by Herindita Puspitaningtyas (11618232)

Subjects:

Growth on stiff substrate results in mild lifespan extension but a decrease in organismal health. by Maria Oorloff (19658113)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

Performance of selected antimalarials against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

Primers used for analysis of four SNPs in one gene. by Winnie Okore (14139712)

Subjects:

Number of samples per site during the study period. by Winnie Okore (14139712)

Subjects:

Performance of selected drugs against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> susceptibility responses of field isolates to antimalarials during the study period. by Winnie Okore (14139712)

Subjects:

<i>Pfmrp1</i> gene SNPs data during the study period. by Winnie Okore (14139712)

Subjects:

Frequency of SNPs in <i>Pfmrp1</i> gene in field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials. by Winnie Okore (14139712)

Subjects: